AR096423A1 - Compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona - Google Patents

Compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona

Info

Publication number
AR096423A1
AR096423A1 ARP140102071A ARP140102071A AR096423A1 AR 096423 A1 AR096423 A1 AR 096423A1 AR P140102071 A ARP140102071 A AR P140102071A AR P140102071 A ARP140102071 A AR P140102071A AR 096423 A1 AR096423 A1 AR 096423A1
Authority
AR
Argentina
Prior art keywords
dihidro
ona
alkyl
halogen
independently selected
Prior art date
Application number
ARP140102071A
Other languages
English (en)
Inventor
Aebi Johannes
Chen Wenming
Kuhn Bernd
Liu Yongfu
E Martin Rainer
Amrein Kurt
Hornsperger Benoit
Li Dongbo
P Maerki Hans
V Mayweg Alexander
Tan Xuefei
Wang Lisha
Wu Jun
Zhou Mingwei
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR096423A1 publication Critical patent/AR096423A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Reivindicación 1: Compuestos de fórmula (1) en la que R¹, R², R³ y R⁴ se seleccionan independientemente entre H, alquilo y cicloalquilo; R⁵, R⁶, R⁷ y R⁹ se seleccionan independientemente entre H, alquilo, halógeno e hidroxi; R⁸ y R¹¹ en conjunto forman -CH₂-CH₂; R¹⁰ es H o R¹⁰ y R¹¹ en conjunto forman -(CH₂)ʷ-; A es -C(O)- o -S(O)₂-; B es -C- o -N-; R¹² es alquilo, cicloalquilo o heteroarilo sustituido, en el que heteroarilo sustituido está sustituido con uno a tres sustituyentes seleccionados independientemente entre H, alquilo, cicloalquilo, hidroxi, alcoxi, ciano y halógeno; R¹³ es halógeno, ciano, alcoxi o haloalcoxi; R¹⁴ es H, alquilo o halógeno; m, n y p se seleccionan independientemente entre cero y 1; w es 1, 2 ó 3; con la condición de que se excluyan 2-[5-(1-acetil-pirrolidin-3-il)-piridin-3-il]-5-cloro-3,3-dimetil-2,3-dihidro-isoindol-1-ona y 2-(1-acetil-1,2,3,4,5,6-hexahidro-[3,4]bipiridinil-5-il)-5-cloro-3,3-dimetil-2,3-dihidro-isoindol-1-ona; y sales farmacéuticamente aceptables de los mismos.
ARP140102071A 2013-05-27 2014-05-26 Compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona AR096423A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2013076276 2013-05-27

Publications (1)

Publication Number Publication Date
AR096423A1 true AR096423A1 (es) 2015-12-30

Family

ID=50841775

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140102071A AR096423A1 (es) 2013-05-27 2014-05-26 Compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona

Country Status (13)

Country Link
US (1) US9505742B2 (es)
EP (2) EP3004089B1 (es)
JP (1) JP6581970B2 (es)
KR (1) KR102217285B1 (es)
CN (1) CN105308045B (es)
AR (1) AR096423A1 (es)
CA (1) CA2911473C (es)
ES (1) ES2804271T3 (es)
HK (1) HK1214258A1 (es)
MX (1) MX366678B (es)
RU (1) RU2689421C2 (es)
TW (1) TWI642668B (es)
WO (1) WO2014191336A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201702335VA (en) * 2014-10-08 2017-04-27 Hoffmann La Roche Spirodiamine derivatives as aldosterone synthase inhibitors
CN104529854B (zh) * 2015-01-14 2016-10-05 武汉金联药业有限公司 一种取代氮杂环丁烷类医药中间体化合物的合成方法
CN107325112A (zh) * 2017-06-05 2017-11-07 毛琳琳 具有抗肝炎活性的2H‑苯并[b][1,4]噁嗪并吡唑化合物的制备方法
PL3700902T3 (pl) * 2017-10-27 2023-09-04 Boehringer Ingelheim International Gmbh Inhibitory trpc6
WO2022034146A1 (en) 2020-08-13 2022-02-17 Boehringer Ingelheim International Gmbh Treatment of cognitive impairement associated with schizophrenia
WO2023063851A1 (en) * 2021-10-13 2023-04-20 «Target Medicals» Limited Liability Company Inhibitors of human aldosterone synthase (cyp11b2)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005283326B2 (en) * 2004-09-13 2011-07-21 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
WO2012035078A1 (en) * 2010-09-16 2012-03-22 Novartis Ag 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
MY169043A (en) * 2011-09-15 2019-02-07 Hoffmann La Roche New dihydroquinoline-2-one derivatives
US9353081B2 (en) * 2011-09-23 2016-05-31 Hoffmann-La Roche Inc. Bicyclic dihydroquinoline-2-one derivatives
MY178867A (en) * 2011-11-30 2020-10-21 Hoffmann La Roche New bicyclic dihydroisoquinoline-1-one derivatives

Also Published As

Publication number Publication date
CA2911473A1 (en) 2014-12-04
HK1214258A1 (zh) 2016-07-22
KR102217285B1 (ko) 2021-02-22
JP6581970B2 (ja) 2019-09-25
MX2015016400A (es) 2016-04-11
US9505742B2 (en) 2016-11-29
EP3004089A1 (en) 2016-04-13
MX366678B (es) 2019-07-19
RU2689421C2 (ru) 2019-05-28
CN105308045A (zh) 2016-02-03
US20160075686A1 (en) 2016-03-17
WO2014191336A1 (en) 2014-12-04
BR112015029696A2 (pt) 2017-07-25
ES2804271T3 (es) 2021-02-05
KR20160014669A (ko) 2016-02-11
EP3719019B1 (en) 2022-01-19
RU2015150614A (ru) 2017-07-03
EP3719019A1 (en) 2020-10-07
TW201504237A (zh) 2015-02-01
EP3004089B1 (en) 2020-05-06
TWI642668B (zh) 2018-12-01
JP2016520105A (ja) 2016-07-11
CA2911473C (en) 2022-05-03
CN105308045B (zh) 2017-05-17

Similar Documents

Publication Publication Date Title
AR096423A1 (es) Compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona
AR092742A1 (es) Piridinonas antifibroticas
AR123048A2 (es) Moduladores de p2x7
AR108388A2 (es) Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas
AR092347A1 (es) Derivados de azaindol
AR103297A1 (es) Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina
AR095198A1 (es) Derivados de triazolona de piridinilo y piridinilo fusionado
AR103252A1 (es) Compuestos de quinazolina
AR106301A1 (es) Composiciones de pirrolpirimidina como inhibidores de quinasas
AR093036A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
AR099363A1 (es) Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil y pirrolo[2,3-d]piridinil acrilamidas
AR104208A1 (es) Compuestos bicíclicos como inhibidores de autotaxina (atx)
AR103742A1 (es) Derivados de trifluorometilpropanamida
AR089051A1 (es) Compuestos de 2-(fenilo sustituido)-ciclopentan-1,3-diona y derivados de los mismos
AR095359A1 (es) Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina
AR104856A1 (es) Derivados de difluorocetamida
AR097571A1 (es) Compuestos espirocíclicos como inhibidores de la triptofano hidroxilasa
AR097866A1 (es) Derivados de 4-azaindol
AR100806A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR105991A1 (es) Heteroarilos sustituidos con pirazolilo y su uso como medicamentos
AR100810A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR091519A1 (es) Inhibidores pirrolopirazona de tanquirasa
AR100940A1 (es) Derivados de 1,2,4-triazoles plaguicidas, y sus intermediarios, composiciones y sus procesos relacionados
AR092223A1 (es) Derivados biciclicos de piridina
AR095884A1 (es) Derivados biaromáticos antibacterianos

Legal Events

Date Code Title Description
FG Grant, registration